Free Trial

AbbVie (ABBV) Stock Price, News & Analysis

AbbVie logo
$189.92 +4.30 (+2.32%)
Closing price 03:59 PM Eastern
Extended Trading
$189.86 -0.06 (-0.03%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About AbbVie Stock (NYSE:ABBV)

Key Stats

Today's Range
$184.39
$191.76
50-Day Range
$173.72
$198.62
52-Week Range
$163.52
$218.66
Volume
5.94 million shs
Average Volume
6.25 million shs
Market Capitalization
$335.47 billion
P/E Ratio
80.82
Dividend Yield
3.45%
Price Target
$211.29
Consensus Rating
Moderate Buy

Company Overview

AbbVie Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
99th Percentile Overall Score

ABBV MarketRank™: 

AbbVie scored higher than 99% of companies evaluated by MarketBeat, and ranked 17th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AbbVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 16 buy ratings, 8 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    AbbVie has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about AbbVie's stock forecast and price target.
  • Earnings Growth

    Earnings for AbbVie are expected to grow by 13.57% in the coming year, from $12.31 to $13.98 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AbbVie is 80.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.87.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AbbVie is 80.82, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.31.

  • Price to Earnings Growth Ratio

    AbbVie has a PEG Ratio of 1.21. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    AbbVie has a P/B Ratio of 99.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about AbbVie's valuation and earnings.
  • Percentage of Shares Shorted

    0.84% of the float of AbbVie has been sold short.
  • Short Interest Ratio / Days to Cover

    AbbVie has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AbbVie has recently decreased by 7.49%, indicating that investor sentiment is improving significantly.
  • Dividend Leadership

    AbbVie is a leading dividend payer. It pays a dividend yield of 3.60%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    AbbVie has been increasing its dividend for 53 years.

  • Dividend Coverage

    The dividend payout ratio of AbbVie is 279.15%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, AbbVie will have a dividend payout ratio of 46.92% next year. This indicates that AbbVie will be able to sustain or increase its dividend.

  • Read more about AbbVie's dividend.
  • Percentage of Shares Shorted

    0.84% of the float of AbbVie has been sold short.
  • Short Interest Ratio / Days to Cover

    AbbVie has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AbbVie has recently decreased by 7.49%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    AbbVie has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 92 news articles for AbbVie this week, compared to 60 articles on an average week.
  • Search Interest

    Only 93 people have searched for ABBV on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.
  • MarketBeat Follows

    Only 25 people have added AbbVie to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AbbVie insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.08% of the stock of AbbVie is held by insiders.

  • Percentage Held by Institutions

    70.23% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about AbbVie's insider trading history.
Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

ABBV Stock News Headlines

Top Stock Reports for Alphabet, AbbVie & Walt Disney
The #1 AI Energy Stock
Nearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being built now will dwarf everything that came before them. Thanks to AI's ravenous hunger for power … They are beginning to morph into sprawling behemoths.
AbbVie’s New CLL Study: Potential Market Impact
See More Headlines

ABBV Stock Analysis - Frequently Asked Questions

AbbVie's stock was trading at $177.70 at the beginning of 2025. Since then, ABBV stock has increased by 6.9% and is now trading at $189.92.
View the best growth stocks for 2025 here
.

AbbVie Inc. (NYSE:ABBV) announced its quarterly earnings data on Friday, April, 25th. The company reported $2.46 EPS for the quarter, beating analysts' consensus estimates of $2.40 by $0.06. AbbVie's revenue for the quarter was up 8.4% compared to the same quarter last year.
Read the conference call transcript
.

The following companies are subsidiaries of AbbVie: Mavupharma, Allergan, Stem CentRx, Pharmacyclics Inc, ImmuVen, AbbVie AB, AbbVie AG, and more.

Top institutional shareholders of AbbVie include Park National Corp OH (0.01%), Rowlandmiller & PARTNERS.ADV, Harbor Investment Advisory LLC and Cullen Investment Group LTD.. Insiders that own company stock include Richard A Gonzalez, Azita Saleki-Gerhardt, Robert A Michael, Nicholas Donoghoe, Jeffrey Ryan Stewart, Timothy J Richmond, Roxanne S Austin, Carrie C Strom, Elaine K Sorg, Scott T Reents, Perry C Siatis and Kevin K Buckbee.
View institutional ownership trends
.

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AbbVie investors own include NVIDIA (NVDA), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), Chevron (CVX), Vanguard Short-Term Inflation-Protected Securities ETF (VTIP), Salesforce (CRM) and Intact Financial (IFC).

Company Calendar

Record date for 5/15 Dividend
4/15/2025
Ex-Dividend for 5/15 Dividend
4/15/2025
Last Earnings
4/25/2025
Dividend Payable
5/15/2025
Today
7/01/2025
Record date for 8/15 Dividend
7/15/2025
Ex-Dividend for 8/15 Dividend
7/15/2025
Next Earnings (Estimated)
7/24/2025
Dividend Payable
8/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Large Cap Pharma
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:ABBV
Employees
55,000
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$211.29
High Stock Price Target
$250.00
Low Stock Price Target
$180.00
Potential Upside/Downside
+11.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.81
Research Coverage
27 Analysts

Profitability

Trailing P/E Ratio
80.76
Forward P/E Ratio
15.42
P/E Growth
1.21
Net Income
$4.28 billion
Pretax Margin
6.31%

Debt

Sales & Book Value

Annual Sales
$56.33 billion
Cash Flow
$15.54 per share
Price / Cash Flow
12.21
Book Value
$1.90 per share
Price / Book
99.89

Miscellaneous

Outstanding Shares
1,766,400,000
Free Float
1,764,990,000
Market Cap
$335.24 billion
Optionable
Optionable
Beta
0.50

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NYSE:ABBV) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners